Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35333444/
New appetite-regulating antiobesity treatments such as semaglutide and agents under investigation such as tirzepatide show promise in achieving weight loss of 15% or more. Energy expenditure, fat oxidation, and lean...
Conclusions: We suggest that the regulatory guidelines should be revisited to focus more on the quality of weight loss and its maintenance rather than the absolute weight loss. Commitment to this research focus both from a scientific and from a regulatory point of view could signal the beginning of the next era in obesity therapies
Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35266164/
doi: 10.1111/apt.16794. Online ahead of print. 1 Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2 Spirit Medical Communications,...
Conclusions: These studies support the use of GLP-1RAs for the improvement of underlying metabolic dysfunction observed in NASH and suggest further long-term phase III trials are warranted.
-
Michelle Jardine4yrI have found GLP-1's extremely helpful in reducing patient's weight although it is not sustainable and patient followed up 6 months to 12 months thereafter did not continue to lose Show More
-
Type 2 Diabetes Connect4yrKey Points • Source: Alimentary Pharmacology and Therapeutics • Conclusion/Relevance: “These studies support the use of GLP-1RAs for the improvement of underlying metabolic dysfunction observed in NASH and suggest further Show More
Association of MRI‐based adrenal gland volume and impaired glucose metabolism in a population‐based cohort study
Source : https://onlinelibrary.wiley.com/doi/10.1002/dmrr.3528
Esther Askani , Susanne Rospleszcz , Wolfgang Rathmann , Annette Peters , Corinna Storz , Corresponding Author Corinna Storz Department of Neuroradiology, Medical Center - University of Freiburg, Faculty of...
Conclusions: Among the 4 GLP-1RAs, Semaglutide was the most cost-effective obesity medication.
-
Dr Hamid4yrAdrenal gland volume may represent an indirect marker of impaired glucose metabolism and HPA axis dysfunction.
Association between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients with Type 2 Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35303075/
doi: 10.1210/clinem/dgac164. Online ahead of print. 1 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 2 Department of...
Conclusion: Compared to DPP4is, SGLT2is use was associated with reduced risks of ESRD and ARF, and a slower eGFR decline in a real-world setting. The associations remained significant in patients with or without pre-index rapid eGFR decline.
-
Dr Hamid4yrDiabetic kidney disease is a major burden among diabetic patients. Sodium-glucose co-transporter 2 inhibitors (SGLT2is) were shown to reduce renal outcomes in clinical trials and real-world studies
Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904982/
Ying Hu,# 1 , # ^ Shui-Lian Zheng,# 1 , # Xiao-Lan Ye, 1 Jia-Na Shi, 1 Xiao-Wei Zheng, 1 Han-Sheng Pan, 1 Yi-Wen Zhang, 1 , 2 Xiu-Li Yang,...